Published in Immunity on April 12, 2012
Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell (2015) 4.16
Tissue-resident macrophages. Nat Immunol (2013) 4.09
Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell (2014) 2.78
Apoptotic cell clearance: basic biology and therapeutic potential. Nat Rev Immunol (2014) 2.59
Clearing the dead: apoptotic cell sensing, recognition, engulfment, and digestion. Cold Spring Harb Perspect Biol (2013) 2.00
The resolution of inflammation. Nat Rev Immunol (2012) 1.58
Alternatively activated macrophages derived from monocytes and tissue macrophages are phenotypically and functionally distinct. Blood (2014) 1.53
Redox control of inflammation in macrophages. Antioxid Redox Signal (2013) 1.39
MicroRNA let-7c regulates macrophage polarization. J Immunol (2013) 1.23
Phagocytosis of apoptotic cells in homeostasis. Nat Immunol (2015) 1.20
Resolution of acute inflammation bridges the gap between innate and adaptive immunity. Blood (2014) 1.09
The paradox of chronic neuroinflammation, systemic immune suppression, autoimmunity after traumatic chronic spinal cord injury. Exp Neurol (2014) 1.02
miR-125a-5p regulates differential activation of macrophages and inflammation. J Biol Chem (2013) 1.02
Resolution of inflammation: a new therapeutic frontier. Nat Rev Drug Discov (2016) 1.02
Novel keto-phospholipids are generated by monocytes and macrophages, detected in cystic fibrosis, and activate peroxisome proliferator-activated receptor-γ. J Biol Chem (2012) 0.92
New families of bioactive oxidized phospholipids generated by immune cells: identification and signaling actions. Blood (2012) 0.91
Female-Specific Downregulation of Tissue Polymorphonuclear Neutrophils Drives Impaired Regulatory T Cell and Amplified Effector T Cell Responses in Autoimmune Dry Eye Disease. J Immunol (2015) 0.90
Interaction between cytokines and inflammatory cells in islet dysfunction, insulin resistance and vascular disease. Diabetes Obes Metab (2013) 0.90
Adipogenic role of alternatively activated macrophages in β-adrenergic remodeling of white adipose tissue. Am J Physiol Regul Integr Comp Physiol (2015) 0.89
Emerging roles of eosinophils and eosinophil-derived lipid mediators in the resolution of inflammation. Front Immunol (2012) 0.89
Proresolution lipid mediators in multiple sclerosis - differential, disease severity-dependent synthesis - a clinical pilot trial. PLoS One (2013) 0.89
Beyond apoptosis in lupus. Curr Opin Rheumatol (2014) 0.87
Macrophage proliferation, provenance, and plasticity in macroparasite infection. Immunol Rev (2014) 0.85
O death where is thy sting? Immunologic tolerance to apoptotic self. Cell Mol Life Sci (2013) 0.85
Innate sensing of oxidation-specific epitopes in health and disease. Nat Rev Immunol (2016) 0.84
Lipid peroxidation generates biologically active phospholipids including oxidatively N-modified phospholipids. Chem Phys Lipids (2014) 0.84
Contrasting phagosome pH regulation and maturation in human M1 and M2 macrophages. Mol Biol Cell (2014) 0.83
12- and 15-lipoxygenases in adipose tissue inflammation. Prostaglandins Other Lipid Mediat (2012) 0.83
Toll-like receptor 7 stimulates production of specialized pro-resolving lipid mediators and promotes resolution of airway inflammation. EMBO Mol Med (2013) 0.83
12/15-Lipoxygenase-mediated enzymatic lipid oxidation regulates DC maturation and function. J Clin Invest (2015) 0.83
The role of nucleotides and purinergic signaling in apoptotic cell clearance - implications for chronic inflammatory diseases. Front Immunol (2014) 0.81
The role of lipoxygenases in pathophysiology; new insights and future perspectives. Redox Biol (2015) 0.81
Phagocyte-myocyte interactions and consequences during hypoxic wound healing. Cell Immunol (2014) 0.80
Tumor immunotherapy: lessons from autoimmunity. Front Immunol (2014) 0.80
Regulation and consequences of monocytosis. Immunol Rev (2014) 0.79
The Dynamics of Apoptotic Cell Clearance. Dev Cell (2016) 0.78
The effect of oxidized phospholipids on phenotypic polarization and function of macrophages. Free Radic Biol Med (2017) 0.78
Concise Review: Mechanisms Behind Apoptotic Cell-Based Therapies Against Transplant Rejection and Graft versus Host Disease. Stem Cells (2016) 0.78
Death-defining immune responses after apoptosis. Am J Transplant (2014) 0.77
Oxidized PLs and vascular inflammation. Curr Atheroscler Rep (2013) 0.77
"Eat me" imaging and therapy. Adv Drug Deliv Rev (2016) 0.77
Oxygenated lipids: a mode to WiPE out inflammation? Immunity (2012) 0.76
MicroRNA-34a Negatively Regulates Efferocytosis by Tissue Macrophages in Part via SIRT1. J Immunol (2015) 0.76
A novel role for 12/15-lipoxygenase in regulating autophagy. Redox Biol (2014) 0.76
The contribution of arachidonate 15-lipoxygenase in tissue macrophages to adipose tissue remodeling. Cell Death Dis (2016) 0.75
Macrophage origin limits functional plasticity in helminth-bacterial co-infection. PLoS Pathog (2017) 0.75
Distinct responses of lung and liver macrophages to acute endotoxemia: role of toll-like receptor 4. Exp Mol Pathol (2012) 0.75
Maxed out macs: physiologic cell clearance as a function of macrophage phagocytic capacity. FEBS J (2016) 0.75
Myeloid 12/15-LOX regulates B cell numbers and innate immune antibody levels in vivo. Wellcome Open Res (2017) 0.75
Context-Dependent Role of Oxidized Lipids and Lipoproteins in Inflammation. Trends Endocrinol Metab (2016) 0.75
A Novel Subset of Anti-Inflammatory CD138(+) Macrophages Is Deficient in Mice with Experimental Lupus. J Immunol (2017) 0.75
Macrophage 11β-HSD1 deficiency promotes inflammatory angiogenesis. J Endocrinol (2017) 0.75
The levels of DNGR-1 and its ligand-bearing cells were altered after human and simian immunodeficiency virus infection. Immunol Res (2017) 0.75
MicroRNA 155-deficiency leads to decreased autoantibody levels and reduced severity of nephritis and pneumonitis in pristane-induced lupus. PLoS One (2017) 0.75
The pathogenesis of rheumatoid arthritis. N Engl J Med (2011) 12.16
Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol (2007) 8.47
Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science (2006) 8.13
Dickkopf-1 is a master regulator of joint remodeling. Nat Med (2007) 7.29
Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A (2010) 5.05
Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol (2013) 4.33
Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest (2012) 4.31
Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science (2008) 4.11
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol (2005) 3.05
Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum (2007) 3.02
Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med (2008) 2.97
The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol (2010) 2.93
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med (2013) 2.93
Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest (2002) 2.85
Regulatory T cells protect from local and systemic bone destruction in arthritis. J Immunol (2010) 2.70
Autophagy regulates TNFα-mediated joint destruction in experimental arthritis. Ann Rheum Dis (2012) 2.66
Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun (2012) 2.65
Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol (2012) 2.59
Periarticular bone structure in rheumatoid arthritis patients and healthy individuals assessed by high-resolution computed tomography. Arthritis Rheum (2010) 2.54
Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum (2002) 2.52
Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res (2007) 2.50
Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheumatol (2015) 2.39
Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J Immunol (2010) 2.38
I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med (2005) 2.21
Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) (2009) 2.14
Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum (2007) 2.12
Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation (2004) 2.08
Relations of vitamin D status, gender and type 2 diabetes in middle-aged Caucasians. Acta Diabetol (2014) 2.07
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis (2012) 2.06
Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med (2011) 2.05
Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus. Arthritis Rheum (2009) 2.04
Generation and biological activities of oxidized phospholipids. Antioxid Redox Signal (2010) 2.04
Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation. J Exp Med (2009) 2.03
Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med (2006) 2.00
Blockade of TNF-α rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci U S A (2011) 1.95
The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat Immunol (2004) 1.95
Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum (2004) 1.94
Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIB and dectin-1. Nat Med (2012) 1.93
Epoxycyclopentenone-containing oxidized phospholipids restore endothelial barrier function via Cdc42 and Rac. Circ Res (2004) 1.88
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis (2014) 1.88
Clearance deficiency and systemic lupus erythematosus (SLE). J Autoimmun (2007) 1.87
Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation. Arthritis Rheum (2006) 1.83
Detection of "Candidatus Neoehrlichia mikurensis" in two patients with severe febrile illnesses: evidence for a European sequence variant. J Clin Microbiol (2010) 1.82
Early structural changes in cartilage and bone are required for the attachment and invasion of inflamed synovial tissue during destructive inflammatory arthritis. Ann Rheum Dis (2012) 1.81
Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med (2006) 1.80
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis (2012) 1.78
Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block. J Clin Invest (2006) 1.76
Multi-hit inhibition of circulating and cell-associated components of the toll-like receptor 4 pathway by oxidized phospholipids. Arterioscler Thromb Vasc Biol (2008) 1.76
Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res (2005) 1.76
Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study. Rheumatology (Oxford) (2011) 1.74
How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum (2008) 1.74
Stringent doxycycline-dependent control of gene activities using an episomal one-vector system. Nucleic Acids Res (2005) 1.74
Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum (2002) 1.72
Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype? Arthritis Rheum (2013) 1.69
Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology (Oxford) (2011) 1.68
Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis (2010) 1.67
PPARβ/δ governs Wnt signaling and bone turnover. Nat Med (2013) 1.66
Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum (2009) 1.65
Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis. Arthritis Rheum (2007) 1.62
TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci U S A (2007) 1.61
Wnt inhibitory factor 1 deficiency uncouples cartilage and bone destruction in tumor necrosis factor α-mediated experimental arthritis. Arthritis Rheum (2013) 1.59
SLE--a disease of clearance deficiency? Rheumatology (Oxford) (2005) 1.59
Integrin α5β1 facilitates cancer cell invasion through enhanced contractile forces. J Cell Sci (2011) 1.59
Leishmania disease development depends on the presence of apoptotic promastigotes in the virulent inoculum. Proc Natl Acad Sci U S A (2006) 1.58
Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction? Ann Rheum Dis (2007) 1.58
Blockade of the hedgehog pathway inhibits osteophyte formation in arthritis. Ann Rheum Dis (2012) 1.58
The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Ann Rheum Dis (2013) 1.57
Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Ann Rheum Dis (2011) 1.56
Factors masking HMGB1 in human serum and plasma. J Leukoc Biol (2006) 1.56
T cell costimulation molecules CD80/86 inhibit osteoclast differentiation by inducing the IDO/tryptophan pathway. Sci Transl Med (2014) 1.56
Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis Rheum (2004) 1.53
Antibodies to the endoplasmic reticulum-resident chaperones calnexin, BiP and Grp94 in patients with rheumatoid arthritis and systemic lupus erythematosus. Rheumatology (Oxford) (2010) 1.53
The evolution of human anti-double-stranded DNA autoantibodies. Proc Natl Acad Sci U S A (2005) 1.53
Schistosoma mansoni triggers Dectin-2, which activates the Nlrp3 inflammasome and alters adaptive immune responses. Proc Natl Acad Sci U S A (2010) 1.50
Liver X receptors orchestrate osteoblast/osteoclast crosstalk and counteract pathologic bone loss. J Bone Miner Res (2012) 1.49
Oxidized phospholipids induce expression of human heme oxygenase-1 involving activation of cAMP-responsive element-binding protein. J Biol Chem (2003) 1.49
Segmentation and quantification of bone erosions in high-resolution peripheral quantitative computed tomography datasets of the metacarpophalangeal joints of patients with rheumatoid arthritis. Rheumatology (Oxford) (2013) 1.48
Bone- and cartilage-protective effects of a monoclonal antibody against colony-stimulating factor 1 receptor in experimental arthritis. Arthritis Rheumatol (2014) 1.48
Osteitis and synovitis, but not bone erosion, is associated with proteoglycan loss and microstructure damage in the cartilage of patients with rheumatoid arthritis. Ann Rheum Dis (2013) 1.47